Companies
T2 Biosystems
its T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from blood without waiting for culture, continuing to publish clinical-benefit data and advance its product pipeline.
- Country
- United States
- Ticker
- TTOO
Growth
T2Resistance Panel
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $7.2 million (2023-12-31) | sec.gov |
| Revenue | $8.3 million in product revenue (2024-12-31) | sec.gov |
| Headcount | 113 employees (2023-12-31) | macrotrends.net |
| Production site | Lexington, Massachusetts and Wilmington, Massachusetts | investors.t2biosystems.com · t2biosystems.gcs-web.com · sec.gov |
| Certification | ISO 13485:2016 certification | sec.gov |
| Regulatory approval | CE marked in the EU for the T2Resistance Panel; FDA Breakthrough Device designation granted for the U.S. T2Resistance Panel | carb-x.org · sec.gov |
| Capacity | Facilities in Lexington and Wilmington, Massachusetts are considered adequate for current manufacturing needs with additional space available for expansion | investors.t2biosystems.com · t2biosystems.gcs-web.com · sec.gov |
| Funding | $2.0 million from CARB-X in 2017; milestone-based contract with BARDA with an initial value of $6 million and potential value up to $69 million | carb-x.org · t2biosystems.gcs-web.com · sec.gov |
Independent sources: carb-x.org · macrotrends.net · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Rapid antibiotic-resistance tests | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.